News




Professor Joanne Martin is President-Elect of The Royal College of Pathologists

Date: 10 Nov 2016

Professor Joanne Martin, BioMoti co-founder and Advisor, has been elected by Fellows of The Royal College of Pathology to be their next president. Professor Martin was appointed President-Elect at the College’s Annual General Meeting. Professor Martin said: “I am very honoured that College Fellows have given me the opportunity to serve my College. I will […]


Read The Rest →







Physiomics Plc do not meet conditions to complete acquisition

Date: 21 Sep 2016

Previously, BioMoti announced on 18th August 2016, the signature of a conditional Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). However, due to not meeting the main condition, Physiomics Plc raising a minimum of £1 million in a placing, the acquisition will not complete. Physiomics Plc did complete a placing of £555 […]


Read The Rest →







Signing of Share Purchase Agreement with Physiomics Plc

Date: 18 Aug 2016

BioMoti is pleased to announce that it has signed a Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). This follows our announcement on 31st March 2016 of non-binding Heads of Terms agreement with Physiomics Plc. The acquisition remains conditional on Physiomics Plc completing a successful placing to raise a minimum of £1 […]


Read The Rest →







Non-Binding Heads of Terms with Physiomics Plc

Date: 31 Mar 2016

BioMoti is pleased to announce that it has signed a non-binding Heads of Terms agreement to be acquired by Physiomics Plc (AIM: PYC). The Proposed Acquisition is currently conditional on a number of items, including due diligence and a successful equity fundraise. For more details, please click to read the Physiomics Plc regulatory update


Read The Rest →







BioMoti CEO interviewed on PharmaTelevision

Date: 25 Jun 2015

Dr Davidson Ateh, BioMoti CEO, discusses BioMoti’s technology, achievements and plans in an interview with Dr Fintan Walton for PharmaTelevision. Please click here to watch the interview


Read The Rest →







BioMoti is featured in UK biotech documentary

Date: 06 May 2015

Earlier this year, Dr Davidson Ateh, CEO, welcomed Philip Hemme and Joachim Eeckhout from LaBiotech Tour to Queen Mary University of London’s QMB Innovation Centre and Blizard Institute during their documentary tour of the UK’s biotech clusters. LaBiotech Tour is the first collection of documentary films about the world’s most vibrant biotech ecosystems. Find out […]


Read The Rest →







BioMoti is featured in the winter issue of the QMB Newsletter

Date: 11 Dec 2014

Dr Davidson Ateh, CEO, discusses efforts to bring BioMoti to an international audience in this winter issue of the QMB Newsletter. The article reviews three trips to the US under UKTI support and a couple to China organised by the Open Innovation unit at the University of Bradford with sponsorship from Yorkshire Cancer Research and AstraZeneca. […]


Read The Rest →







Professor Linton and BioMoti awarded MRC Studentship

Date: 13 Mar 2014

We are very pleased to announce the award of a Medical Research Council Industrial CASE Studentship to Professor Kenneth Linton of Queen Mary University of London in collaboration with BioMoti. This prestigious training grant will support a standout PhD student to study the basic cellular and molecular biology mechanisms underpinning ‘targeting cancer cells with CD95R-coated […]


Read The Rest →







BioMoti is shortlisted for OBN 2013 award

Date: 23 Aug 2013

BioMoti is very pleased to announce that it is shortlisted in the Best Emerging Biotech category (Sponsored by James Cowper) alongside Atopix Therapeutics and Autifony Therapeutics for the OBN Awards 2013. The winners in each of ten categories will be announced at the OBN Annual Awards Dinner taking place on 1 October 2013 at the Ashmolean Museum of Art […]


Read The Rest →







BioMoti is featured in sp2 Inter-Active May/June 2013 issue

Date: 05 Jun 2013

Dr Davidson Ateh, CEO, discusses BioMoti’s Oncojan™ intracellular drug delivery technology for cancer treatment with Tom Mulligan, Editor, in the May/June 2013 edition of sp2 Inter-Active. The article explores the origins of BioMoti, it’s technological capabilities, lead ovarian cancer candidate, business model, growth plans and the current context for early stage UK biotech companies. Click for article: BioMoti […]


Read The Rest →